|Bid||14.21 x 1000|
|Ask||14.30 x 800|
|Day's Range||14.05 - 14.37|
|52 Week Range||8.60 - 19.77|
|Beta (3Y Monthly)||1.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 12, 2018 - Mar 16, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.00|
Pulse Biosciences, Inc. (PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company bringing to market its proprietary CellFX™ System, announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 23,750 shares of Pulse Biosciences common stock to three recently hired non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on October 15, 2019. The 2017 Inducement Equity Incentive Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pulse Biosciences as an inducement material to such individual’s entering into employment with Pulse Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
-- Histological Effects of NPS-Treated Dermal Skin on Sebaceous Glands and Sebaceous Hyperplasia Lesions Spotlights “Facial Rejuvenation” Session at the American Academy of Facial
Every investor in Pulse Biosciences, Inc. (NASDAQ:PLSE) should be aware of the most powerful shareholder groups...
Pulse Biosciences, Inc. (NASDAQ:PLSE) shareholders might understandably be very concerned that the share price has...
Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary CellFX™ System today announced that the Company will report first quarter 2019 operational highlights and financial results on Tuesday, April 30, 2019.
Pulse Biosciences, Inc. , a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced that key findings from its clinical programs using Nano-Pulse Stimulation™ technology will be presented at the American Society for Laser Medicine and Surgery’s Annual Conference being held March 27-31, 2019, in Denver, CO.
Pulse Biosciences, Inc.(PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced the appointment of Mitchell Levinson to its board of directors. In connection with his appointment to the board, Mr. Levinson will also serve as a member of the audit committee. Levinson, 58, has more than 25 years of experience bringing novel medical technologies to the market, including over a decade in the aesthetics procedure market.
Pulse Biosciences’ patented Nano-Pulse Stimulation™ technology (“NPS™”), delivered by its proprietary, tunable CellFX System, is characterized by the delivery of a series of nanosecond duration electrical energy pulses, with pulse durations from billionths up to a millionth of a second.
Pulse Biosciences, Inc. (PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System today announced the Premarket Notification 510(k) submission to the U.S. Food and Drug Administration (FDA) for its CellFX System. The Company’s FDA filing requests clearance of the CellFX System for commercial use in common dermatologic procedures to remove general benign lesions including sebaceous hyperplasia (SH), a common but difficult to treat facial lesion and seborrheic keratosis (SK), the most common benign raised pigmented lesion. Pursuant to Section 510(k), once the application has been accepted, the FDA will conduct its substantive review and may request additional information from the Company based on that review.